Published in Nat Commun on July 09, 2015
Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature (2016) 0.92
Structure of glycosylated NPC1 luminal domain C reveals insights into NPC2 and Ebola virus interactions. FEBS Lett (2016) 0.85
Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med (2016) 0.75
Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 Å resolution. Sci Rep (2017) 0.75
A comparison of host gene expression signatures associated with infection in vitro by the Makona and Ecran (Mayinga) variants of Ebola virus. Sci Rep (2017) 0.75
Fighting Ebola: A Window for Vaccine Re-evaluation? PLoS Pathog (2017) 0.75
Human genetic variation in VAC14 regulates Salmonella invasion and typhoid fever through modulation of cholesterol. Proc Natl Acad Sci U S A (2017) 0.75
Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med (2014) 16.45
Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res (2012) 9.65
Ebola haemorrhagic fever. Lancet (2011) 8.28
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature (2014) 6.94
CD-HIT Suite: a web server for clustering and comparing biological sequences. Bioinformatics (2010) 6.68
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell (1999) 5.16
The GxxxG motif: a framework for transmembrane helix-helix association. J Mol Biol (2000) 5.09
Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell (1998) 4.73
Molecular code for transmembrane-helix recognition by the Sec61 translocon. Nature (2007) 4.60
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med (2000) 4.36
Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A (1998) 4.33
Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science (1998) 4.24
Enzymic characterization and lipid composition of rat liver subcellular membranes. Biochim Biophys Acta (1971) 4.09
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol (2002) 3.62
Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat Cell Biol (2000) 3.55
[On the etiology of an unknown human infection originating from monkeys]. Dtsch Med Wochenschr (1967) 3.14
Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science (2001) 3.08
Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol (2002) 3.06
Vesicular release of ebola virus matrix protein VP40. Virology (2001) 3.03
Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol (1998) 2.99
Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog (2011) 2.99
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature (2014) 2.98
Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol (2004) 2.92
Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses. Cell (1996) 2.70
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
The role of lipid rafts in T cell antigen receptor (TCR) signalling. Semin Immunol (2000) 2.64
Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol (2000) 2.59
Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology (2000) 2.33
In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A (2003) 2.32
Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol (2001) 2.13
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Biosynthesis and role of filoviral glycoproteins. J Gen Virol (2001) 1.84
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature (2015) 1.76
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol (2000) 1.62
Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol (2005) 1.61
Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J (2006) 1.60
Filovirus assembly and budding. Virology (2006) 1.56
Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol (2005) 1.47
Molecular recognition of a single sphingolipid species by a protein's transmembrane domain. Nature (2012) 1.42
Oligomerization and polymerization of the filovirus matrix protein VP40. Virology (2003) 1.42
Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog (2010) 1.29
Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol (2009) 1.23
Filovirus budding. Virus Res (2004) 1.21
Lipid cell biology. Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins. Science (2014) 1.17
Post-exposure therapy of filovirus infections. Trends Microbiol (2014) 1.17
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog (2012) 1.16
Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Virology (2008) 1.14
Glutamate-binding affinity of Drosophila metabotropic glutamate receptor is modulated by association with lipid rafts. Proc Natl Acad Sci U S A (2003) 1.10
The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis (2011) 1.10
The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress. J Biol Chem (2013) 1.07
Differential cholesterol binding by class II fusion proteins determines membrane fusion properties. J Virol (2008) 1.06
Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog (2014) 1.06
Filovirus entry: a novelty in the viral fusion world. Viruses (2012) 1.03
A practical treatment for patients with Ebola virus disease. J Infect Dis (2014) 1.01
The multiple roles of sGP in Ebola pathogenesis. Viral Immunol (2015) 0.98
Stiffened lipid platforms at molecular force foci. Proc Natl Acad Sci U S A (2013) 0.97
Disposition of amphiphilic helices in heteropolar environments. Proteins (1997) 0.91
Treatment of ebola virus disease. Pharmacotherapy (2015) 0.90
Labeling of cholesterol with filipin in cellular membranes of parenchymatous organs. Standardization of incubation conditions. Histochemistry (1987) 0.89
World struggles to stop Ebola. Nature (2014) 0.79
Pre-symptomatic diagnosis and treatment of filovirus diseases. Front Microbiol (2015) 0.77
Reply to Fedson. J Infect Dis (2014) 0.76